CN106110206A - A kind of Chinese medicine preparation treating endometriosis and preparation method thereof - Google Patents
A kind of Chinese medicine preparation treating endometriosis and preparation method thereof Download PDFInfo
- Publication number
- CN106110206A CN106110206A CN201610632470.9A CN201610632470A CN106110206A CN 106110206 A CN106110206 A CN 106110206A CN 201610632470 A CN201610632470 A CN 201610632470A CN 106110206 A CN106110206 A CN 106110206A
- Authority
- CN
- China
- Prior art keywords
- parts
- ethanol
- preparation
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 85
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 53
- 241000218176 Corydalis Species 0.000 claims abstract description 30
- 239000009286 sanguis draxonis Substances 0.000 claims abstract description 30
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 306
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 88
- 239000000284 extract Substances 0.000 claims description 87
- 239000000843 powder Substances 0.000 claims description 50
- 239000008187 granular material Substances 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 32
- 239000002244 precipitate Substances 0.000 claims description 30
- 239000006228 supernatant Substances 0.000 claims description 24
- 238000001556 precipitation Methods 0.000 claims description 23
- -1 reflux Substances 0.000 claims description 22
- 229920002472 Starch Polymers 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000006286 aqueous extract Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 241000219061 Rheum Species 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 14
- 108010011485 Aspartame Proteins 0.000 claims description 13
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 13
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 13
- 239000000605 aspartame Substances 0.000 claims description 13
- 229960003438 aspartame Drugs 0.000 claims description 13
- 235000010357 aspartame Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 244000178320 Vaccaria pyramidata Species 0.000 claims description 6
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims 1
- 239000006068 taste-masking agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 39
- 210000004369 blood Anatomy 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 35
- 208000002193 Pain Diseases 0.000 abstract description 31
- 230000036407 pain Effects 0.000 abstract description 29
- 230000001737 promoting effect Effects 0.000 abstract description 12
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 55
- 238000000605 extraction Methods 0.000 description 49
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 39
- 239000012567 medical material Substances 0.000 description 33
- 230000008569 process Effects 0.000 description 31
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 26
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 238000001035 drying Methods 0.000 description 21
- 229930182470 glycoside Natural products 0.000 description 21
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 21
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 19
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 19
- 150000002338 glycosides Chemical class 0.000 description 19
- 235000005875 quercetin Nutrition 0.000 description 19
- 229960001285 quercetin Drugs 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 14
- 239000000341 volatile oil Substances 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 13
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 13
- 239000006071 cream Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229930003944 flavone Natural products 0.000 description 10
- 235000011949 flavones Nutrition 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 229930182487 phenolic glycoside Chemical class 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 239000013558 reference substance Substances 0.000 description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 9
- 208000005171 Dysmenorrhea Diseases 0.000 description 8
- 150000004056 anthraquinones Chemical class 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 208000021267 infertility disease Diseases 0.000 description 8
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000002481 ethanol extraction Methods 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 150000002989 phenols Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 150000007950 phenolic glycosides Chemical class 0.000 description 6
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 6
- 235000018553 tannin Nutrition 0.000 description 6
- 229920001864 tannin Polymers 0.000 description 6
- 239000001648 tannin Substances 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 239000010282 Emodin Substances 0.000 description 5
- 208000019255 Menstrual disease Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 150000008425 anthrones Chemical class 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 240000004980 Rheum officinale Species 0.000 description 3
- 235000008081 Rheum officinale Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000009835 oxypaeoniflora Substances 0.000 description 3
- FCHVXNVDFYXLIL-QYDSDWLYSA-N oxypaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@@]1(C[C@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=C(O)C=C1 FCHVXNVDFYXLIL-QYDSDWLYSA-N 0.000 description 3
- RLXWQODPAWIVOI-UHFFFAOYSA-N oxypaeoniflorin Natural products OCC1OC(OC23CC4C5(O)CC2OC(O5)C34COC(=O)c6ccc(O)cc6)C(O)C(O)C1O RLXWQODPAWIVOI-UHFFFAOYSA-N 0.000 description 3
- 208000010669 pelvic lump Diseases 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
- UICBHOXXGLYZJH-UHFFFAOYSA-N 5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium Chemical compound C1=CC=C2CC[N+]3=CC4=CC=CC=C4C=C3C2=C1 UICBHOXXGLYZJH-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 241001251200 Agelas Species 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N Benzylformate Chemical compound O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- BPLQKQKXWHCZSS-UHFFFAOYSA-N Elemicin Chemical compound COC1=CC(CC=C)=CC(OC)=C1OC BPLQKQKXWHCZSS-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010021033 Hypomenorrhoea Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 240000001745 Rheum palmatum Species 0.000 description 2
- 235000008090 Rheum palmatum Nutrition 0.000 description 2
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- LOAQRYJNIQZQQB-UHFFFAOYSA-N benzo[k]phenanthridine;isoquinoline Chemical class C1=NC=CC2=CC=CC=C21.C1=CC=CC2=C3C4=CC=CC=C4C=CC3=CN=C21 LOAQRYJNIQZQQB-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- 235000001671 coumarin Nutrition 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229930182489 iridoid glycoside Natural products 0.000 description 2
- 150000008145 iridoid glycosides Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 235000008777 kaempferol Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 229930186851 sennoside Natural products 0.000 description 2
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- NITWSHWHQAQBAW-QPJJXVBHSA-N (E)-4-coumaric acid methyl ester Chemical compound COC(=O)\C=C\C1=CC=C(O)C=C1 NITWSHWHQAQBAW-QPJJXVBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- IPQVTOJGNYVQEO-LALZNDFESA-N 9-[(9r)-2-carboxy-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-LALZNDFESA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- CYNUMZCJGCZYTD-UHFFFAOYSA-N Swertianolin Natural products O1C2=C(O)C=CC(O)=C2C(=O)C=2C1=CC(OC)=CC=2OC1OC(CO)C(O)C(O)C1O CYNUMZCJGCZYTD-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- MSBHOJSEFZPTET-UHFFFAOYSA-N isorhamnetin 3-O-galactoside Natural products OCC1OC(OC2=C(Oc3c(O)ccc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C(O)C1O MSBHOJSEFZPTET-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- RTATXGUCZHCSNG-ZFDPGQBLSA-N nicotiflorin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RTATXGUCZHCSNG-ZFDPGQBLSA-N 0.000 description 1
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical class C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- KRXANNXAPJODKJ-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranoside Natural products OCC1OC(COC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C(O)C1O KRXANNXAPJODKJ-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000001290 saussurea lappa clarke root oil Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- XMVBNLMKPMPWAX-DIKOWXHZSA-N swertianolin Chemical compound C=1C(OC)=CC(O)=C(C(C2=3)=O)C=1OC2=C(O)C=CC=3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XMVBNLMKPMPWAX-DIKOWXHZSA-N 0.000 description 1
- XMVBNLMKPMPWAX-UHFFFAOYSA-N swertianoline Natural products C=1C(OC)=CC(O)=C(C(C2=3)=O)C=1OC2=C(O)C=CC=3OC1OC(CO)C(O)C(O)C1O XMVBNLMKPMPWAX-UHFFFAOYSA-N 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000010887 waste solvent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Chinese medicine preparation treating endometriosis and preparation method thereof, count by weight, be made up of following crude drug: Sanguis Draxonis 53~198 parts, Radix Et Rhizoma Rhei 99~495 parts, Fructus Corni 198~396 parts, Radix Angelicae Sinensis 198~396 parts, Cortex Moutan 198~396 parts, the Radix Aucklandiae 99~330 parts, Rhizoma Corydalis 99~330 parts, Radix Paeoniae Rubra 198~396 parts, Poria 293~495 parts, Rhizoma Curcumae 173~297 parts, Herba Polygoni cymosi 105~990 parts, Ramulus Cinnamomi 99~330 parts and Rhizoma Sparganii 165~330 parts.The Chinese medicine preparation of the treatment endometriosis of the present invention, blood circulation promoting and blood stasis dispelling, the kidney invigorating takes off admittedly, and dissipate knot, removing obstruction in the collateral to relieve pain, has the effect of good treatment endometriosis.The preparation technology of the present invention is simple, feasible, stable, and preparation condition gentleness is easy to control, simple to operate, it is easy to large-scale production.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation treating endometriosis and preparation method thereof, belong to traditional Chinese medicine technology neck
Territory.
Background technology
Endometriosis refers to the endometrium with growth function, is covered in other portions of the health beyond cavity of uterus
, there is a kind of gynaecopathia of cyclic hemorrhage repeatedly simultaneously in position.Ectopic Endometrium functionally can be along with the change of estrogen level
Change, also can produce significantly change, not only have the body of gland of inner membrance, also have inner membrance interstitial around.Endometriosis is main
Occurring at pelvic organ, cervix uteri, vagina, perineum and abdominal incision are likely to there will be, and have the strongest transformation and business growth ability, for
Common gynecological disease disease.Gynecopathy is common in the women of child-bearing age more, and its sickness rate ascendant trend in recent years is very fast, the wherein women of child-bearing age
Account for more than 10%, and relapse rate is high.The clinical manifestation of gynecopathy not necessarily has the strongest phase with the degree of pathological changes sometimes
Guan Xing, when the lesion degree of patient lighter or local, its clinical manifestation may be very serious, and when the extent of disease of patient
Pelvic Anatomy structure gross distortion even occur relatively greatly, its clinical manifestation is the lightest.According to statistics, there are about the intrauterine of 70%
Endometriosis patient has typical secondary dysmenorrhea, change in menstrual cycle characteristics, the clinical manifestations such as sexual intercourse is unhappy and infertile.When gynecopathy occurs
When other privileged sites, its clinical manifestation produced may not correspond with this disease.And Most patients cardinal symptom is for continuing
The property sent out dysmenorrhea, is often accompanied by the Progressive symmetric erythrokeratodermia pain at hypogastric region and back, can be radiated to leg.Generally a few days ago start pain in menstruation
Bitterly.When Ectopic Endometrium is hemorrhage, menstruation reaches summit.The Most patients pain in menstrual period is eased.But late
In patient, especially having the adhesion of popularity in pelvic cavity, its pain may proceed to exist.Typical secondary dysmenorrhea patient age base
These are between 30~45 years old.Its focus can cause the retroversion of patient.The sick time of patient is the longest, its dyspareunia, property
Handing over pain, the symptom such as dyspareunia is the most obvious, and endometriosis and about 1/3rd unknown causes is infertile relevant.Should
The incidence of infertility of condition subject is also up to 40%.The change of anatomical structure is probably one of infertile reason of severe patient in late period.Gently
The reason that degree patient is infertile has the biggest contacting with intraperitoneal microenvironment factor, ovarian function exception etc..
Without the record of " endometriosis " name of disease in Chinese medicine ancient documents, but according to gynecopathy main clinical manifestation,
Can belong among the disease such as " dysmenorrhea ", " abdominal mass ", " menoxenia ", " infertile ".The most different according to Gynecology of Chinese Medicine in recent decades
The more systematic research of disease, it is believed that " stagnation of blood stasis uterus, punching " is its basic pathogenesis occurred, and function and vim and vigour
Imbalance, the factor such as exopathogen invasion is relevant to the formation of the stasis of blood.The diagnoses and treatment of " gynecopathy " is by Chinese medicine
Its fundamental characteristic, Chinese medicine thinks, the main symptom of " gynecopathy " is syndrome of blood stasis, and through the whole process of disease.The disease initial stage with
Excess syndrome is main, and just, because of the real void that causes, rare pure deficiency syndrome, master shows as simulataneous insufficiency and excessive disease to sick long wound.True person, premenstrual dysmenorrhea, menstrual period
Sharp ache, tenderness.Simulataneous insufficiency and excessive person, menstrual period dysmenorrhea, through after pain gesture the most slow.Because trembling with fear and stasis of blood person, for cold type of pain, angor, obtain burning pain
Subtract;Because of thermic stasis of blood person, for causalgia, obtain burning pain and increase;Because of stagnation of QI person, swollen pendant is had a pain;Blood stasis notably, for twinge.Because of the stagnation of QI or cold coagulation
Causing stasis of blood person, hypomenorrhea, color is purple dark, has clot.Because of hot or damp and hot and stasis of blood person, many through amount, color depth is red, and matter is thick clot.Deficiency of vital energy blood
Stasis of blood person, also many also few through amount, color is light dim, matter dilute folder clot.By dialectical to this disease of the traditional Chinese medical science, be generally divided into syndrome of qi stagnation and blood stasis,
The type such as cold blood stasis card, blood stasis due to renal deficiency card, damp and hot syndrome of blood stasis.
Chinese medicine has modern medicine pair between its original advantage, particularly recent decades on treatment endometriosis
Endometriosis research steps is accelerated, and understanding and the exploration of endometriosis are the most progressively deepened, no by Chinese medicine
It is only in symptom, observe single curative effect, observes Chinese medicine to endometriosis effect from Microscopic Indexes more simultaneously
Action effect, thus more objectively screen effective and suitable treatment by Chinese herbs method.Chinese medicine is to endometriosis not
Only play its therapeutical effect, also can preferably regulate the many aspects such as endocrine and immunity of body simultaneously.Therefore select
Chinese medicine, takes modern preferably extraction process and preparation technology, prepares medicine, the treatment for endometriosis provided
One true medicable Chinese medicine new varieties, provides new medicine for this patient.
Summary of the invention
For solving the deficiencies in the prior art, it is an object of the invention to provide a kind of Chinese medicine treating endometriosis
Preparation and preparation method thereof.The Chinese medicine preparation of the treatment endometriosis that the present invention provides has good treatment intrauterine
The effect of endometriosis, preparation technology is simple, feasible, stable.
In order to realize above-mentioned target, the present invention adopts the following technical scheme that:
A kind of Chinese medicine preparation treating endometriosis, counts by weight, is made up of following crude drug: Sanguis Draxonis
53~198 parts, Radix Et Rhizoma Rhei 99~495 parts, Fructus Corni 198~396 parts, Radix Angelicae Sinensis 198~396 parts, Cortex Moutan 198~396 parts, the Radix Aucklandiae
99~330 parts, Rhizoma Corydalis 99~330 parts, Radix Paeoniae Rubra 198~396 parts, Poria 293~495 parts, Rhizoma Curcumae 173~297 parts, Herba Polygoni cymosi
105~990 parts, Ramulus Cinnamomi 99~330 parts and Rhizoma Sparganii 165~330 parts.
Further, the Chinese medicine preparation for the treatment of endometriosis is counted by weight, is made up of following crude drug: dragon
Sanguis Draxonis 103 parts, Radix Et Rhizoma Rhei 412 parts, Fructus Corni 343 parts, Radix Angelicae Sinensis 275 parts, Cortex Moutan 275 parts, the Radix Aucklandiae 175 parts, Rhizoma Corydalis 257 parts,
Radix Paeoniae Rubra 223 parts, 343 parts of Poria, Rhizoma Curcumae 223 parts, Herba Polygoni cymosi 155 parts, Ramulus Cinnamomi 223 parts and Rhizoma Sparganii 223 parts.
Previous formulations be make excipient with soluble starch, 0.2% aspartame makees correctives, wetting agent made by 90% ethanol
The granule made.
The preparation method of the Chinese medicine preparation for the treatment of endometriosis, comprises the following steps: weigh Herba Polygoni cymosi, mountain according to quantity
The Fructus Evodiae, Rhizoma Corydalis and rhubarb medicinal material, add ethanol, reflux, extract, filter, obtain alcohol extract, standby;Weigh according to quantity Sanguis Draxonis, Radix Angelicae Sinensis,
Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii, add water, and decocts and extracts, and filters, obtains Aqueous extracts, through concentrating under reduced pressure,
Obtain condensed water extract, add ethanol, stir, stand, discard precipitation, obtain precipitate with ethanol supernatant, standby;Alcohol extract and precipitate with ethanol
Supernatant mixes, concentrating under reduced pressure, obtains concentrated solution, and concentrated solution is vacuum dried, and obtains extractum extract, pulverizes and sieves, obtains medicated powder, then
Add adjuvant and make various pharmaceutical preparation.
Specifically, the preparation method of the Chinese medicine preparation of aforementioned therapies endometriosis, comprise the following steps: claim according to quantity
Take Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and rhubarb medicinal material, add 6~10 times amount 60%~80% ethanol, reflux, extract, 1~3 times, often
Secondary 1~2h, filter, obtain alcohol extract, standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, osmanthus according to quantity
Branch and Rhizoma Sparganii, add 6~10 times amount water, decocts and extracts 1~3 time, and each 1~2h filter, obtain Aqueous extracts, through 75 DEG C of concentrating under reduced pressure
Being 1.05 to density, obtain condensed water extract, add ethanol, stir, controlling concentration of alcohol in feed liquid is 40%~60%,
Stand 12h, discard precipitation, obtain precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density
It is 1.25, obtains concentrated solution, concentrated solution 60 DEG C~80 DEG C vacuum drying 72~42h, obtain extractum extract, pulverized No. 5 sieves, and obtained
Medicated powder, adds adjuvant and makes various pharmaceutical preparation.
Preferably, the preparation method of the Chinese medicine preparation of aforementioned therapies endometriosis, comprise the following steps: claim according to quantity
Take Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and rhubarb medicinal material, add 9 times amount, 8 times amount 80% ethanol respectively, reflux, extract, 2 times, every time
1h, filters, obtains alcohol extract, standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and three according to quantity
Rib, adds 7 times amount, 6 times amount water respectively, decocts and extracts 2 times, and each 1h filters, obtains Aqueous extracts, be evaporated to density through 75 DEG C
Being 1.05, obtain condensed water extract, add ethanol, stir, controlling concentration of alcohol in feed liquid is 60%, stands 12h, discards
Precipitation, obtains precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentration
Liquid, concentrated solution 70 DEG C vacuum drying 60h, obtain extractum extract, pulverized No. 5 sieves, and obtained medicated powder, and added adjuvant and make various
Pharmaceutical preparation.
Further, the preparation method of the Chinese medicine preparation of aforementioned therapies endometriosis, is by the mass ratio of 1:1
Adding soluble starch in medicated powder, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, and 90% ethanol is made to moisten
Humectant is pelletized, and granule is dried in 60 DEG C~80 DEG C, and secondary is pelletized, and crosses and screens out bulky grain and except fine powder, obtains granule.
More specifically, the preparation method of the Chinese medicine preparation of aforementioned therapies endometriosis, it is by the mass ratio of 1:1
Adding soluble starch in medicated powder, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, and 90% ethanol is made to moisten
Humectant is pelletized, and granule gradually rises warming middle-JIAO at 60 DEG C~80 DEG C and is dried, and secondary is pelletized, and crosses No. 1 and screens out bulky grain, crosses No. 5 and screens out thin
Powder, obtains granule.
The Chinese medicine preparation of the treatment endometriosis of the present invention, with Herba Polygoni cymosi and Sanguis Draxonis as monarch drug, Cortex Moutan, prolongs
Rhizoma Corydalis and Radix Paeoniae Rubra are ministerial drug, and Radix Et Rhizoma Rhei, Fructus Corni, the Radix Aucklandiae, Rhizoma Curcumae and Rhizoma Sparganii are adjuvant drug, and Radix Angelicae Sinensis, Ramulus Cinnamomi and Poria are for making medicine.
In order to ensure the science, reasonable, feasible of the present invention program, by carrying out series of experimental research and investigation, thus
Determine the solution of the present invention.
One, the selection of crude drug in the present invention:
1, Sanguis Draxonis nature and flavor are sweet, salty flat, nontoxic, have effect of promoting blood circulation to remove blood stasis, pain relieving, hemostasis, promoting tissue regeneration and ulcer healing.Wherein contain
Resin about 57.5%, for the derivant of flavonoid.More to its chemical constitution study in recent years.Its liposoluble constituent is studied
Middle separation also identifies 6 fat-soluble compounds.It has blood circulation promoting and blood stasis dispelling and hemostasis convergence two-ways regulation, anti-inflammatory and antalgic, antibacterial
Deng effect.
2, Rhizoma Sparganii bitter in the mouth, property are put down, and enter liver, spleen channel, have the effect such as removing blood stasis circulation of qi promoting, removing food stagnancy pain relieving, be conventional invigorating blood circulation
Stasis of blood Chinese medicine.Volatile oil, organic acid, steroid, flavonoid, Phenylpropanoid Glycosides class etc. are its main chemical compositions.There is anti-blood little
Plate coagulation and antithrombotic, on effects such as the impact of hemorheological property, analgesias.
3, Herba Polygoni cymosi, for the aerial parts of polygonaceae plant Herba Polygoni cymosi, have another name called pass through leaf knotweed, Herba Lespedezae Cuneatae, Herba Polygoni cymosi, Herba Damnacanthi,
Plough point grass etc., all herbal medicine, for perennial climing property draft, all there is distribution all parts of the country, aboundresources.Begin to be loaded in " ten thousand sick times
Spring ", now record the Pharmacopoeia of the People's Republic of China one (version in 2010).Property acid, bitter, flat, there is heat-clearing and toxic substances removing, parasite killing only
Itch, effect of dispelling wind stopping cough, inducing diuresis to remove edema, the treatment edema that is widely used among the people, jaundice, malaria, dysentery, pertussis, ulcer, red
Poison, eczema, herpes, scabies and venom etc., determined curative effect.In Herba Polygoni cymosi root isolation identification go out cupreol, trans-to hydroxyl
Base methyl cinnamate, Quercetin, Quercetin-3-O-β-D-glucopyranoside, rheum emodin, physcione and aloe-emodin etc. are changed
Compound.Containing phenols, organic acid, alkaloid, aminoacid, tannin, flavone, anthraquinone, glycoside, saccharide, plant sterol and triterpenes
Etc. chemical composition.Herba Polygoni cymosi Med Mat Appreciation kaempferol, Quercetin, storage glycosides, Quercetin-3-O-β-D-Glucose aldehydic acid methyl ester,
The flavone compounds such as Quercetin-3-β-D-Glucose aldehydic acid N-butyl, KAEMPFEROL-3-O-RUTINOSIDE, rutin.Herba Polygoni cymosi has
There are the effects such as antiinflammatory antibacterial, eliminating phlegm and stopping cough, antiviral.
4, Radix Et Rhizoma Rhei is polygonum rheum palmatum (Rheum palmatum L.), Rheum tanguticum (Rheum
TanguticumMaxim.ex Balf.) or the dry root and rhizome of Rheum officinale (Rheum officinale Baill.).In
Medicine Radix Et Rhizoma Rhei is one of special product of China medicine, and bitter in the mouth is cold in nature, returns stomach, spleen, large intestine, liver, pericardium channel, has purging heat and dredging bowels, removing heat from blood solution
The effects such as poison, eliminating blood stasis and inducing menstruation.Shennong's Herbal is said: " lower blood stasis, blood closes cold and heat, broken abdominal mass accumulation, and prolonged fluid-retention dyspepsia cleanses intestinal
Stomach, pushes away Chen Zhixin, tonneau water paddy, relieving dyspepsia in tune, peace and the five internal organs ".Compendium of Material Medica: " dysentery is red in vain, and pain in the abdomen is suffered from abdominal pain, urine leaching
Drip, excess-heat dryness accumulated in the stomach and intestine, the quiet language of hectic fever, yellow cellulitis, all burn ".Anthraquinone derivatives is active component main in Radix Et Rhizoma Rhei.Anthraquinones spreads out
Biology includes anthrone class rheum emodin (Emodin), chrysophanic acid (Rhein), chrysophanol (Chrysophano1), physcione
(Physcion), the effective ingredient such as aloe-emodin (Aloe-emodin) and chrysaron (Chrysaron);Radix Et Rhizoma Rhei possibly together with
Glycoside that Radix Et Rhizoma Rhei anthraquinone analog derivative and glucose are combined into and anthrone class, such as sennoside (Sennoside) A, B, C, D, E, F
Deng, and other glycosides, tannin, compound of polysaccharide, organic compound and inorganic matter etc..Radix Et Rhizoma Rhei has blood and metabolic system
Impact, hemostasis, blood fat reducing, rush down under, heat-clearing and toxic substances removing, anti-inflammation, hepatic cholagogic effect.
5, Radix Angelicae Sinensis has benefiting blood and regulating blood circulation, regulating menstruation, hemostasis, effect of intestine moistening laxation, for parts of generic medicinal plants.Can be used for blood deficiency to wither
The treatment of Huang, dizziness cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia etc..Research shows, its
Comprise the multiple active ingredient such as volatile oil, polysaccharide.
6, Rhizoma Curcumae is conventional Chinese medicine, its acrid in the mouth warm in nature, has circulation of qi promoting removing blood stasis, effect of removing food stagnancy pain relieving.For blood stasis amenorrhea,
Dyspeptic abdominal distention etc..Research show to have preferable antitumor, antithrombotic, antiinflammatory, antiviral, antiearly pregnancy, antibacterial, protect the liver, anti-fibre
Dimensional tissue hypertrophy etc. act on.It it is the activating blood and removing stasis drug the most more commonly used.Its active component is volatile oil, modern pharmacology
Research shows, its have preferable antitumor, antithrombotic, antiinflammatory, antiviral, antiearly pregnancy, antibacterial, protect the liver, anti-psoriasis, anti-fibre
The multiple pharmacological effect such as dimensional tissue hypertrophy.
7, Poria is a kind of Mycophyta Chinese medicine.Sweet in the mouth, light flat.GUIXIN, lung, kidney channel.There are promoting diuresis to eliminate damp pathogen, spleen invigorating, calm the nerves
Effect modern pharmacological research proves, it has diuresis, regulation immunity, calmness, antitumor, protects the liver etc. and to act on, and is clinically used for edema
The treatment of the cards such as oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, loose stool are had loose bowels, irritability, is widely used.
8, Ramulus Cinnamomi is recorded in Shennong's Herbal the earliest, comes from " Newly Revised Canon of Materia Medica ", property of medicine temperature, acrid-sweet flavor, current 12 warps.
GUIXIN, lung, bladder warp, have relieving the exterior syndrome by diaphoresis, supporing yang activating QI, effect of relieving the exterior syndrome by diaphoresis, and it is contained within volatile oil, also the benzyl in formic acid
Ester, acetic acid meat ester, coumarin, Rhizoma Acori Graminei alkene etc..There is the effect such as antiviral, antibacterial, antipyretic-antalgic, antiinflammatory, antiallergic.
9, the root bark of Cortex Moutan system Ranunculaceae Paeonia plant Paeonia suffruticosa (Paenoina SuffruticosaAndr).Property is micro-
Cold, bitter in the mouth, pungent.GUIXIN, liver, kidney channel.Cortex Moutan is divided into part more, is mainly composed of phenol and phenolic glycoside class, monoterpene and glycoside thereof,
Also have triterpene, sterol and glycoside, flavone, organic acid, coumarin etc..In Cortex Moutan, phenol and phenolic glycoside class are the classes that content is higher
Compound, the phenol therefrom separated and phenolic glycoside compounds have: paeonol, Cortex Moutan phenolic glycoside, the former glycosides of paeonol, paeonol are new.Its tool
There are the regulation of atherosclerosis, blood pressure lowering, blood sugar lowering, convulsion, urinary system, regulation immunocyte, antibacterial and anti-inflammation functions.
10, Fructus Corni has the effect such as liver and kidney tonifying, essence astringing and desertion stemming, is usually used in dizziness, tinnitus, soreness of waist and knee joint, sexual impotence, loses
Essence, the enuresis, frequent micturition, leucorrhoea hemorrhage, profuse sweating collapses, and interior-heat such as is quenched one's thirst the disease.Iridoid glycosides, Pentacyclic triterpenic acid and esters thereof,
Tannin class, polysaccharide are the chemical composition that it is main.There is blood sugar lowering, antibacterial, antiinflammatory, and immune system can be affected.
11, Rhizoma Corydalis acrid in the mouth, hardship, warm in nature, returns liver, spleen channel;Have invigorate blood circulation, promoting the circulation of QI, effect of pain relieving.Main chemical compositions
For isoquinoline type alkaloid, being divided into two kinds by the dissolubility in water, tertiary amine base is the most insoluble or is insoluble in water;Quaternary amine alkali is easier to
It is dissolved in water.Up to now, therefrom separate and through the existing kind more than 40 of Structural Identification, adhere to separately proto-berberine, aporphine, former Ah
Sheet bases, isoquinolin benzyl imidazoles, isoquinolin benzo phenanthridines class, double benzyl different beautiful jade class etc..There are blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain
Effect, modern experimental proves that it has well analgesia, calm, blood pressure lowering and antiarrhythmic effect.Have invigorate blood circulation, circulation of qi promoting,
The effect of pain relieving;For pylorus ligation and the gastric ulcer of aspirin-induced, there is significant protective effect, and can effectively suppress right
Gastric secretion;Its total alkaloids also has protective effect to ischemic myocardial.
12, Radix Paeoniae Rubra is Paeoniaceae plant peony (Paeonia Lacti floraPall.) or river Radix Paeoniae Rubra (P.veit chii
Lynch) dry root, nature and flavor are bitter, are slightly cold, return Liver Channel, have effect of clearing away heat and cooling blood, eliminating stasis to stop pain.For maculae caused by violent heat pathogen, tell
Blood epistaxis, conjunctival congestion and swelling pain, hypochondriac pain due to stagnation of liverQI, amenorrhea dysmenorrhea, lump in the abdomen stomachache, injury from falling down, carbuncle skin infection.The main of Radix Paeoniae Rubra effectively becomes
Divide the methods of glycosides mainly with peoniflorin as representative, including paeoniflorin (paeoniflorin), oxypaeoniflorin (oxy-
Paeoniflorin) etc..Again containing dextrorotation cachou extract (catechin) and volatile oil.Benzoic acid (benzoic acid) is volatile oil
Main component, paeonol (paeonol) and other alcohols and phenols component totally 33.Tool antithrombus formation, antiplatelet aggregation,
Blood fat reducing and arteriosclerosis effect.
13, the Radix Aucklandiae returns spleen;Stomach;Liver;The pungent acrid in the mouth of lung meridian;Bitter;Warm in nature.Have and regulate the flow of vital energy in tune, drying dampness to eliminate phlegm promoting the circulation of QI to relieve pain;Adjust
Middle intestinal stasis relieving.Main born of the same parents coerce distension foot;Abdominal distention;Tell and have loose bowels;Weight after dysentery.After breast gastral cavity distending pain, dysentery, weight, food stagnation are not
Disappear, anorexia, there is antibacterial action.Its pungent temperature is fragrant to be dissipated, and can rise and can drop, lead to the gas managing three Jiao, especially benefaction gastrointestinal gas and
Pain relieving, has the merit of strengthening the spleen to promote digestion concurrently, is usually used in all cards caused by all taste QI stagnation of the large intestine.
Two, the determination of preparation technology
1 decoction pieces source
Decoction pieces used is purchased from Guizhou Ji Rentang pharmaceutcal corporation, Ltd, identified meets " Chinese Pharmacopoeia " version one in 2010
Relevant regulations under portion and " Guizhou Province's Chinese crude drug, Ethnic crude drugs quality standard " version each medical material (decoction pieces) item in 2003.
2 process routes determine, preferably
The determination of 2.1 extracting method
The Chinese medicine preparation extracting method for the treatment of endometriosis is based on the chemical composition character of each flavour of a drug in prescription
Study with modern pharmacology, and combine the factor designs such as industrialized production reality.
Containing sufficiently complex chemical composition in Sanguis Draxonis.According to the structure of phenolic compound, chalcone derivative can be roughly divided into,
The polymer of 2-hydrogen chalcone derivative, flavanone, flavone, flavonoid, chromone class, flavone compound and other phenolic compound.Mesh
Front separated to steroidal, triterpene substance 21 kinds.Outside including the compound such as phenols, steroidal saponin, there is also other structure
The compound of type, such as: alkane, acids, esters etc..Can obtain from the current research overview about its chemical composition, Sanguis Draxonis master
Wanting composition is phenoloid, is wherein main status with flavone compound.Cure mainly according to we's function, take its water extract-alcohol precipitation
Fractions.
Chemical composition in Rhizoma Sparganii is mainly volatile oil, organic acid, steroid, flavonoid, Phenylpropanoid Glycosides class etc..In recent years
Come, constantly have new component, new activity to be found.At present, it has therefore proved that its total flavones has antiplatelet aggregation, antithrombotic, analgesia
Effect.Available water extract-alcohol precipitation extracts.
Herba Polygoni cymosi chemical composition has phenols, organic acid, alkaloid, aminoacid, tannin, flavone, anthraquinone, glycoside, saccharide, plants
Thing sterol and triterpenes etc..In root isolation identification go out cupreol, trans-p-Coumaric Acid methyl ester, Quercetin, Quercetin-
The compounds such as 3-O-β-D-Glucose glycoside, rheum emodin, physcione and aloe-emodin.Med Mat Appreciation kaempferol, Cortex querci dentatae
Element, storage glycosides, Quercetin-3-O-β-D-Glucose aldehydic acid methyl ester, Quercetin-3-β-D-Glucose aldehydic acid N-butyl, kaempferol-3-
The flavone compounds such as O-rutinoside, rutin.Effective ingredient can be proposed to greatest extent with ethanol extraction.
Active component main in Radix Et Rhizoma Rhei is anthraquinone derivatives.Anthraquinone derivatives includes anthrone class rheum emodin, Radix Et Rhizoma Rhei
Acid, chrysophanol, physcione, aloe-emodin and chrysaron etc.;Radix Et Rhizoma Rhei is possibly together with Radix Et Rhizoma Rhei anthraquinone analog derivative and Fructus Vitis viniferae
Glycoside that sugar is combined into and anthrone class, such as Sennoside A, B, C, D, E, F etc., and other glycosides, tannin, compound of polysaccharide, organic
Compound and inorganic matter etc..Effective ingredient can be proposed to greatest extent with ethanol extraction.
Pharmacological component main in Radix Angelicae Sinensis is volatile oil, polysaccharide etc..Possibly together with sucrose, fructose, glucose;Vitamin
A, vitamin B12, vitamin E;17 kinds of aminoacid and sodium, potassium, calcium, magnesium etc. more than 20 plant inorganic elements.According to we function master
Control, take its water extract-alcohol precipitation fractions.
The active component of Rhizoma Curcumae is volatile oil, and content is 1.9%~2.5%.In recent years the composition in volatile oil was carried out
Research, in oil, main chemical compositions is multiple sesquiterpenoids material.Possibly together with zinc, ferrum, nickel, manganese, magnesium, cadmium, copper, molybdenum, cobalt,
The various trace elements such as vanadium, phosphorus, calcium, gallium.Available water extract-alcohol precipitation extracts.
Poria is mainly composed of polysaccharide, accounts for the 9.3% of dry weight, in addition possibly together with triterpenoid compound.Also containing fat
Fat acid, such as octanoic acid, undecanoic acid, lauric acid, lauric acid/dodecanoic acid and Palmic acid.Additionally, also ergosterol, natural gum, chitin, albumen
Matter, fat, sterol, lecithin, D-glucose, adenine, histidine, choline, lipase, protease etc..According to we's merit
Can cure mainly, take its water extract-alcohol precipitation fractions.
Ramulus Cinnamomi main active is volatile oil, and volatile oil content reaches 0.6%, additionally containing benzyl formate, acetic acid meat ester,
Coumarin, Rhizoma Acori Graminei alkene etc..Available water extract-alcohol precipitation extracts.
The composition being separated in Cortex Moutan is more complicated, but main with phenol and phenolic glycoside class, monoterpene and glycoside thereof, and other also have three
Terpene, sterol and glycoside thereof, flavone, organic acid, coumarin etc..Phenol and phenolic glycoside class phenol and phenolic glycoside compounds content in Cortex Moutan
Higher, the phenol and the phenolic glycoside compounds that are separated to from Cortex Moutan have: paeonol, Cortex Moutan phenolic glycoside, the former glycosides of paeonol, paeonol
Newly.Available water extract-alcohol precipitation extracts.
The main chemical compositions of Fructus Corni is iridoid glycosides, Pentacyclic triterpenic acid and esters thereof, tannin class, polysaccharide.
Its volatile ingredient mainly has: Palmic acid, isobutanol, isoamyl alcohol, elemicin, furfural, methyleugenol, different asarone, β-
Phenethanol etc..Glucoside and glycoside unit include: venbenalin, morroniside, swertianolin, Semen Strychni glycoside, iridoids, Fructus Vitis viniferae
Sugar, fructose and sucrose.Effective ingredient can be proposed to greatest extent with ethanol extraction.
The main chemical compositions of Rhizoma Corydalis is isoquinoline type alkaloid, can be divided into two kinds according to its dissolubility in water,
Tertiary amine base is the most insoluble or the person that is insoluble in water;Person more soluble in water belongs to quaternary amine alkali.Up to the present, therefrom isolate and pass through knot
The existing kind more than 40 that structure is identified, its type is belonging respectively to again proto-berberine, aporphine, protopine class, isoquinolin benzyl miaow
Azole, isoquinolin benzo phenanthridines class, double benzyl different beautiful jade class etc..Effective ingredient can be carried to greatest extent with ethanol extraction
Go out.
The principle active component of Radix Paeoniae Rubra is that the methods of glycosides with peoniflorin as representative is containing paeoniflorin, oxypaeoniflorin etc..Again
Containing dextrorotation cachou extract and volatile oil.Volatile oil is mainly containing benzoic acid, paeonol and other alcohols and phenols component totally 33.Available
Decoction and alcohol sedimentation technique extracts, and method is more ripe.
Costus root oil master chemical composition Han lactone, content reaches 50%.Available water extract-alcohol precipitation extracts.
2.2 process routes determine
According to the chemical composition character of each flavour of a drug in prescription, cure mainly in conjunction with prescription function and said extracted methods analyst knot
Really, intend Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis, rhubarb medicinal material in prescription are added ethanol extraction, filter, obtain alcohol extract, standby.Prescription
In remaining 9 taste medicine extracting in water, filter, obtain Aqueous extracts, concentrate, obtain condensed water extract, add ethanol in proper amount precipitate with ethanol, it is heavy to discard
Form sediment, obtain precipitate with ethanol supernatant, standby.Alcohol extract mixes with precipitate with ethanol supernatant and is concentrated to give concentrated solution (recovery ethanol).Concentrated solution is dried,
Obtain extractum extract, pulverize and sieve.Add adjuvant to pelletize, granulate, to obtain final product.Draft process route as shown in Figure 1.
2.3 alcohol extraction process conditions are preferred
2.3.1 the investigation of alcohol rate inhaled by medical material
Medical material three parts, Herba Polygoni cymosi 4.5g, Fructus Corni 10g, Rhizoma Corydalis 7.5g and Radix Et Rhizoma Rhei is weighed by a prescription proportional quantities
12g, altogether 34g, add the soak with ethanol of 5 times amount, observes every 30min and once soaks situation, till being impregnated with medicated core, presses
Formula tries to achieve weight in wet base result, and result is as shown in table 1:
The investigation of alcohol rate inhaled by table 1 medical material
As shown in Table 1, when adding alcohol extraction first, the suction alcohol amount of medical material 108% should be supplied, for convenience of production calculation, first
When adding alcohol extraction, adding a times amount ethanol with whole alcohol extraction medical materials, the ethanol inhaling alcohol amount to be added with theory is more or less the same, therefore
The ethanol adding a times amount first during alcohol extraction is that comparison is rational.
2.3.2 concentration of alcohol and other factors is preferred
(1) concentration of alcohol preferably select the concentration of ethanol to be respectively as follows: 80% according to quercetin component in Herba Polygoni cymosi,
70%, 60% carries out investigating screening.
(2) if extraction time when preferably consideration produces greatly of extraction time is the shortest, effective ingredient is relatively difficult to extract completely,
And the extraction time long cost that can improve, and lose time, therefore extraction time is chosen as tri-kinds of levels of 1h, 1.5h, 2h and investigates.
(3) extraction time the most according to a conventional method, selective extraction number of times be respectively the most once, twice, three times investigate.
(4) quantity of solvent preferably weighs 4 taste pharmaceutical decocting pieces, add the solvent of 5 times amount just can submergence medical material, and solubilization dosage is too
Greatly not only waste solvent, and cause cost to increase, in conjunction with considering the suction alcohol rate of medical material, therefore to select quantity of solvent be 6 times, 8 times, 10
Times amount is investigated.
2.3.3 method and result
(1) method is to seek 4 optimum process condition of ethanol extraction of taste medical material such as Herba Polygoni cymosi, Rhizoma Corydalis, intends with orthogonal
Test table L9 (34) carry out orthogonal test, so that it is determined that optimal ethanol extraction condition.Orthogonal design table is as shown in table 2.
Table 2 L9 (34) orthogonal test factor and level
The preparation of sample solution takes the medical material 17g altogether of half recipe quantity, selects orthogonal table to press the test side of orthogonal trial
Case is carried out, and the alcohol extract of gained, through filtering, being concentrated into 100mL, to obtain final product.
Index components selected with Quercetin in Herba Polygoni cymosi and paste-forming rate as index components, preferably alcohol extraction optimum extraction work
Skill.
Reference substance solution is prepared precision and is weighed Quercetin reference substance in right amount, adds methanol and makes every 1mL 0.09mg Han Quercetin
Solution, to obtain final product.
Need testing solution is prepared precision and is measured sample 10mL under " preparation of sample solution " item, puts in beaker and volatilizes, accurate
Addition 50mL methanol: hydrochloric acid=4:1 solution, weighed weight, 90 DEG C of water-bath reflux, extract, 1h, lets cool, more weighed weight, uses methanol
Supply the weight of less loss, shake up, filter, take subsequent filtrate, to obtain final product.
Dry cream rate measures precision and measures sample solution under 50mL " preparation of sample solution " item, is concentrated into certain density, puts
Water bath method in the evaporating dish of constant weight, 105 DEG C of dry 3h, to constant weight, put cooling 30min, its matter the most accurately weighed in exsiccator
Amount, calculates the rate that gets dry extract.
The extractum weight of W50mL:50mL sample solution
V is total: population of samples amasss
W medical material: medical material weight
(2) quercetin content measurement result
Chromatographic condition Agela promosil C18 (250mm × 4.6,5 μm);With methanol-0.4% phosphate aqueous solution=
50:50 is flowing phase;Detection wavelength is 360nm;Flow velocity: 1.0mL/min;Column temperature: 30 DEG C;In terms of Quercetin theoretical cam curve not
Less than 3000.As shown in Figure 2, Figure 3 and Figure 4.
It is appropriate that standard curve precision weighs Quercetin reference substance, and add methanol dissolving making mass concentration is the right of 90 μ g/mL
According to product solution, inject HPLC by the chromatographic condition drafted and measure.Quercetin sample size is respectively 0.1 μ L, 0.3 μ L, 0.5 μ L, 1 μ
L、2μL.With peak area, sample introduction quality is carried out linear regression, obtain the regression equation of each tested composition, correlation coefficient and linear model
Enclose.Result is as shown in table 3 and Fig. 5: Quercetin mass concentration in 0.009~0.180 μ g range in good linear relation.
Table 3
(3) Orthogonal Experiment and Design and result
The medical material 17g altogether of half recipe quantity is weighed, by L9 (3 by prescription4) orthogonal test condition extracts respectively, filter, just
Step is concentrated into a certain amount of, obtains test liquid.With quercetin content, receipts cream rate as index, use overall merit (overall merit=Cortex querci dentatae
Cellulose content/Quercetin maximum level × 80-receives cream rate/maximum and receives cream rate × 20) it is index, obtain optimised process.Result such as table 4,
Shown in table 5 and table 6.
Table 4 orthogonal experiments
Table 5 orthogonal test variance analysis
Table 6 orthogonal experiment comprehensive grading result
From table, Orthogonal experiment results understands, and it is extraction time that each factor affects the order of alcohol extraction technique > concentration of alcohol >
Ethanol consumption>extraction time, wherein extraction time C, concentration of alcohol A have significance (P<0.05) to affect, therefore, according to orthogonal examination
Testing result, extraction time C most preferably selects C2, concentration of alcohol A most preferably to select A3;And ethanol consumption B, extraction time D there was no significant difference,
Producing in conjunction with big, preferably optimum process condition is A3B2C2D1.The ethanol solution i.e. adding 8 times amount 80% extracts 2 times, each 1h.
2.3.4 test is verified
Weigh the medical material 17g altogether of half recipe quantity, carry out checking test, as shown in table 7, knot by preferred plan A3B2C2D1
Fruit coincide with orthogonal experiments.Illustrate that this process stabilizing is feasible.It is thus determined that alcohol extraction process is: the ethanol of 8 times amount 80% is molten
Liquid reflux, extract, 2 times, each 1h.
Table 7 alcohol extraction process the result
2.4 abstract methods techniques are preferred
2.4.1 the investigation of medical material water absorption rate
Medical material three parts, Cortex Moutan 8g, Poria 10g, Ramulus Cinnamomi 6.5g, Radix Angelicae Sinensis 8g, Rhizoma Sparganii 6.5g, cowherb is weighed by prescription proportional quantities
Art 6.5g, Radix Paeoniae Rubra 6.5g, Radix Aucklandiae 8g and Sanguis Draxonis 3g, 63g altogether, add the water soaking of 7 times amount, observe every 30min and once soak
Bubble situation, till being impregnated with medicated core, tries to achieve weight in wet base result as the following formula, and result is as shown in table 8:
The investigation of table 8 medical material water absorption rate
As shown in Table 8, first during extracting in water, the water absorption of medical material 102% should be supplied, for convenience of production calculation, first
During extracting in water, carrying medical material with whole water and add a times amount water, the water to be added with theoretical water absorption is more or less the same, first
The water adding a times amount when water puies forward is that comparison is rational.
2.4.2 water carries the preferred of factor level
(1) amount of water selects to weigh 9 taste pharmaceutical decocting pieces, add the water of 5 times amount just can submergence medical material, take medical material into consideration
Water absorption rate, therefore selecting amount of water is 6 times, 8 times, 10 times amount investigations.
(2) if extraction time when preferably consideration produces greatly of extraction time is the shortest, effective ingredient is relatively difficult to extract completely,
And the extraction time long cost that can improve, and lose time, therefore extraction time is chosen as tri-kinds of levels of 1h, 1.5h, 2h and investigates.
(3) extraction time the most according to a conventional method, selective extraction number of times be respectively the most once, twice, three times investigate.
2.4.3 method and result
(1) method is to seek 9 optimum process condition of water extraction of taste medical material such as Sanguis Draxonis, Ramulus Cinnamomi, intends with orthogonal test
Table L9 (34) carry out orthogonal test, so that it is determined that optimal water extraction condition, as shown in table 9.
Table 9 L9 (34) orthogonal test factor and level
The preparation of sample solution takes the medical material 31.5g altogether of half recipe quantity, selects orthogonal table to press the test of orthogonal trial
Scheme is carried out, and the Aqueous extracts of gained, through filtering, being concentrated into 100mL, to obtain final product.
Index components selected with peoniflorin in Radix Paeoniae Rubra and paste-forming rate as index, preferably water carries optimum extraction process.
Reference substance solution is prepared precision and is weighed peoniflorin reference substance in right amount, adds methanol and is respectively prepared every 1ml containing peoniflorin 257
The solution of μ g, to obtain final product.
Need testing solution is prepared precision and is measured sample 10mL under " preparation of sample solution " item, puts in beaker and volatilizes, accurate
Add 25mL methanol solution, weighed weight, supersound process 30min, let cool, more weighed weight, the weight of less loss is supplied with methanol,
Shake up, filter, take subsequent filtrate, to obtain final product.
Dry cream rate measures precision and measures sample solution under 50mL " preparation of sample solution " item, is concentrated into certain density, puts
Water bath method in the evaporating dish of constant weight, 105 DEG C of dry 3h, to constant weight, put in exsiccator cooling 30min, and the most accurately weighed it is heavy
Quality, calculates the rate that gets dry extract.
The extractum weight of W50mL:50mL sample solution
V is total: population of samples amasss
W medical material: medical material weight
(2) paeoniflorin content measurement result
Peoniflorin chromatographic condition Agela promosil C18 (250mm × 4.6,5 μm);With methanol-0.5mol/L phosphoric acid
Potassium dihydrogen solution=40:65 is flowing phase;Detection wavelength is 230nm;Flow velocity: 1.0mL/min;Column temperature: 30 DEG C;Manage with peoniflorin
Opinion number of plates meter is not less than 3000.As shown in Fig. 6, Fig. 7 and Fig. 8.
It is appropriate that standard curve precision weighs peoniflorin reference substance, adds methanol dissolving and makes mass concentration 257 μ g/ml's respectively
Reference substance solution, injects HPLC by the chromatographic condition drafted and measures.Peoniflorin sample size be respectively 2.5 μ L, 5 μ L, 12.5 μ L, 20
μL、25μL.With peak area, sample introduction quality is carried out linear regression, obtain the regression equation of each tested composition, correlation coefficient and linear
Scope.Result is as shown in table 10 and Fig. 9: peoniflorin mass concentration in 0.64~6.42 μ g range in good linear relation.
Table 10
Orthogonal Experiment and Design and result
The medical material 31.5g altogether of half recipe quantity is weighed, by L9 (3 by prescription4) orthogonal test condition extracts respectively, filter,
Initial concentration, to a certain amount of, obtains test liquid.With paeoniflorin content and dry cream rate as index, use overall merit (overall merit=
Paeoniflorin content/maximum paeoniflorin content × 80-dry cream rate/maximum dry cream rate × 20) it is index, obtain optimised process.Result is such as
Shown in table 11~table 13.
Table 11 Orthogonal experiment results
Table 12 orthogonal experiment variance analysis
Table 13 orthogonal experiment comprehensive grading result
From table, Orthogonal experiment results understands, and it is extraction time that each factor affects the order in water extraction process > amount of water >
Extraction time, wherein extraction time A has significance (P < 0.05) to affect, and therefore according to orthogonal experiments, extraction time A is optimal
Select A2;And ethanol consumption B, extraction time C there was no significant difference, in conjunction with big Production requirement, preferably optimum process condition it is
A2B1C1.I.e. add 6 times amount water extraction 2 times, each 1h.
2.4.4 test is verified
Weigh the medical material 31.5g altogether of half recipe quantity, carry out checking test, result such as table 14 institute by preferred plan A2B1C1
Show.Result is coincide with orthogonal experiments.Illustrate that this process stabilizing is feasible.It is thus determined that it is 6 times amount water extraction 2 that water put forward work to add skill
Secondary, each 1h.
Table 14 extraction process by water the result
2.5 Aqueous extracts impurity removal process are preferred
Chinese crude drug is after water carries, and often containing starch, polysaccharide, protein, pectin etc. in its liquid, causes final prepared consolidating
Body preparation taking dose is excessive, is purified so generally dealing with extracting solution, reduces the content of unrelated composition in preparation, reduces clothes
Use dosage.In production, the certain density alcohol of many employings carries out precipitate with ethanol impurity removal process.
2.5.1 different alcohol precipitation concentrations are preferred
Weigh the medical material 63g of 3 parts of recipe quantities respectively, add 6 times amount water extraction secondaries, each 1 hour, obtain Aqueous extracts
Concentrating, add a certain amount of ethanol, controlling feed liquid concentration of alcohol respectively is 40%, 50%, 60% precipitate with ethanol, after standing 12 hours
Obtaining alcohol deposit fluid, reconcentration drying under reduced pressure obtains 3 parts of dry cream respectively, and result is as shown in Table 15.
Table 15 water extract-alcohol precipitation concentration of alcohol comparative result
By found that the purification effect feed liquid concentration of alcohol compared with 60% of 40%, 50% is poor, final dosage is still
Bigger.The feed liquid concentration of alcohol purification effect of 60% is preferable, effectively reduces dosage, and the concentration of alcohol of feed liquid is less than
65%, can effectively preserve the effective ingredient such as polysaccharide of prescription, alcohol precipitation concentration to change the impact on paeoniflorin content little, therefore really
The feed liquid concentration of alcohol determining Aqueous extracts precipitate with ethanol purification is 60%.
2.6 concentrations and drying process are preferred
Composition and the character of Chinese medicine extraction liquid Chinese medicine are complex, in concentration, dry run, due to heated time relatively
Long, its some effective ingredient contained may be destroyed to some extent, and makes its active constituent content reduce, and have impact on preparation
Clinical efficacy.Concentrate drying is the important step that Chinese medicine preparation produces, and selects different concentrate drying modes, will affect finished product
Active constituent content, water capacity, outward appearance, color and luster, granularity, dissolubility and hygienic requirements thereof etc. and it is necessary to combine its produce
Scale and production capacity consider concentrate drying technique.The most conventional concentrate drying method is divided into four kinds, has normal pressure to concentrate
Seasoning, concentrating under reduced pressure seasoning, the various ways such as spray drying method and micro-wave drying method.Concentrating under reduced pressure has and prevents from effectively becoming
Point decompose, high efficiency, the shortest, the advantage of energy efficient etc., the big consideration produced after combining, therefore this process choice reduces pressure dense
Contracting.With the rate of transform of Quercetin, paeonol and peoniflorin as evaluation index, to normal pressure and vacuum drying with in condition of different temperatures
Under drying process investigated.
2.6.1 different drying modes are preferred
Weigh the medical material 48.5g altogether of half recipe quantity, carry out alcohol by preferred plan respectively and mention that water carries, remix extracting solution
Concentrating under reduced pressure, to certain density, compares constant pressure and dry, drying under reduced pressure difference drying mode, by investigate Quercetin, paeonol and
The content of peoniflorin be dried before and after contrast, fragitity, color, drying time etc., factor, determined optimum drying mode.Result is such as
Shown in table 16.
The impact of the different drying mode of table 16
As shown in Table 16, consider Quercetin, paeonol and peoniflorin be dried before and after content balance, fragitity, face
Color, on the basis of drying time, selects vacuum drying for optimum drying mode.
2.6.2 different temperatures is on vacuum drying impact
Weigh the medical material 48.5g altogether of half recipe quantity, carry out alcohol by preferred plan respectively and mention that water carries, remix extracting solution
Concentrating under reduced pressure, to certain density, compares and is vacuum dried 80 DEG C, 70 DEG C, the baking temperature of 60 DEG C.Result is as shown in table 17.
The impact of table 17 different vacuum drying time
As shown in Table 17, it is considered to drying efficiency, Quercetin, paeonol, the rate of transform of peoniflorin raise with temperature and reduce.
Although the drying time of 80 DEG C is shorter, but content has larger difference.The content difference of 60 DEG C and 70 DEG C is less, but 60 DEG C are dried effect
Rate is low compared with 70 DEG C, considers from the big efficiency produced, determines that 70 DEG C of vacuum is dried.
(by version " Chinese Pharmacopoeia " requirement in 2010) is calculated after measured, Radix Paeoniae Rubra medical material Radix Paeoniae in test in early stage preliminary experiment
Glycosides content is 19mg/g, and Herba Polygoni cymosi medical material quercetin content is 1.55mg/g.By to the extraction of preparation, purification, concentrate and dry
Drying process is investigated preferably, finally gives the dry plaster powder of preparation.In the target component that preparation is selected, calculate after measured in Radix Paeoniae Rubra
The rate of transform of the Quercetin in peoniflorin and Herba Polygoni cymosi respectively reaches 76% and 61%, illustrate selected extraction, purification, concentration and
Drying process is stable, feasible.
2.7 moulding processs determine
2.7.1 dosage form is preferred
The Chinese medicine preparation recipe quantity for the treatment of endometriosis is 97g, the most once with decoction, evident in efficacy.For
Increase its clinical adaptability, by this prescription under the guidance of Chinese medical theory, use the theory of modernization, technology, method to press
It is processed into certain dosage form according to recipe quantity.Physicochemical property according to each medical material ingredient and modern pharmacological research result and each dose
The feature of type, it is believed that if making liquid preparation, the then poor stability of preparation, preserve, transport inconvenience.The present invention once considered by
Capsule made by this prescription, but is 97g according to the recipe quantity of its clinical application, according to the rate of extract total after its water extract-alcohol precipitation and alcohol extraction
Generally 15%, fill No. 0 capsule, every 0.5g, in the case of being not added with adjuvant, need every day to take 30, which adds
The burden of taking medicine of patient.Therefore consider to make this prescription granule, and increasing the adaptability that patient takes, granule is at human body the intestines and stomach
In road, disintegrate is rapid, absorbs fast, and is readily transported, carries and takes, and in the case of the curative effect ensureing this prescription, adds steady
Qualitative, it is achieved the modernization of this prescription and economic society are worth.
The method of granule the most processed is preferred
Granule processed dry extract can be divided into pelletize according to the method for granulating of different material and thick paste is pelletized.This experiment considers alcohol
Carry solution and water carries solution and is concentrated into relative density 1.30~1.35, add 3~5 times of granulations that adjuvant amount is extractum, result in
The dose of medicine increases, therefore the dry cream of this experimental selection is pelletized.
2.7.3 adjuvant is preferred
(1) anti-moisture absorption agent and excipient are because the dried cream powder of the Chinese medicine granules for the treatment of endometriosis is in the process of preservation
In the easily moisture absorption, therefore consider to select suitable adjuvant as anti-moisture absorption agent and excipient.The present invention intends selecting dextrin, solubility to form sediment
Powder, lactose are as excipient, and when in preliminary experiment, soluble starch is cooked anti-moisture absorption agent and excipient, the viscosity of soft material is low, granule
Molding and mobility are all preferable, and anti-moisture absorption capacity is strong, and soluble starch is water insoluble and ethanol, the most stable,
Moisture absorption and not deliquescence.The chemical property of soluble starch is the most stable, inoperative with most medicine, cheap.
(2) correctives select due to treatment endometriosis Chinese medicine granules raise dried cream powder through alcohol extraction and water
After, its bitter and puckery flavor, it is more difficult in directly oral, therefore consider that adding certain correctives improves its bad smell.Consider that add rectifys
Taste agent has 0.2% aspartame, 0.5% cyclamate or directly replaces part soluble starch as adjuvant with sucrose.Preliminary experiment
Show that adding 0.2% aspartame can be effectively improved the taste of its bitterness.
2.7.4 excipient and medicated powder ratio
Medicated powder is pelletized by different mass ratio 3:4,1:1,4:3,2:1 from soluble starch, observes its granulating efficiency, suction
Moist and outward appearance, the results are shown in Table 18:
Table 18 soluble starch investigates result with medicated powder ratio
From table 18, when the mass ratio of medicated powder Yu soluble starch is 1:1, granule is nonhygroscopic, effect is best, becomes
Type rate is high, therefore determines that medicated powder is 1:1 with the best in quality ratio of soluble starch.
2.7.5 wetting agent is preferred
In order to better ensure that stability and its ratio of briquetting of preparation, this experiment is intended with 80%, 85%, 90%, 95%
Ethanol carries out research of pelletizing, and the results are shown in Table 19:
Table 19 different wetting agent granulation situation
The above results shows, pelletizes with 90% ethanol for wetting agent, soft material moderate viscosity processed, it is easy to pelletize, gained granule
The most moderate, good forming effect, therefore select to make wetting agent with the ethanol of 90%.
2.7.6 the performance indications of granule
(1) bulk density measures and weighs 2g medicated powder (crossing No. four sieves), loads in 10mL graduated cylinder, falls for several times with certain altitude
(keeping consistent), make degree of tightness suitable, with weight and calculation of capacity bulk density, bulk density=weight (g)/volume as far as possible
(mL).The results are shown in Table 20:
Table 20 3 batch sample bulk density measurement result
(2) angle of repose, funnel was drawn a circle to approve on the diagram paper of horizontal positioned by mensuration, and the funnel end opening distance away from diagram paper is
H, pours funnel into granule until the outlet of funnel and round can nib contacts, measures cone base diameter (2R) and circular cone is high
(H), θ is calculated according to tan θ=H/R.The results are shown in Table 21:
Table 21 3 batch sample measurement result angle of repose
Result shows that the average angle of repose of granule is 28.17 degree, illustrates that the mobility of granule is preferable.
2.7.7 the critical relative humidity of granule
Critical relative humidity is medicine moisture absorption whether marginal value, simultaneously can also be according to it is determined that environmental wet when producing
Degree.Prepare sulphuric acid or the saturated solution of different salt of variable concentrations respectively, be respectively placed in 96h in constant temperature (25 DEG C) exsiccator, make
Its interior humidity balance constitutes the environment of different relative humiditys, the results are shown in Table 22:
The sulphuric acid of table 22 variable concentrations or the supersaturated solution of the different salt relative humidity when 25 DEG C
The powder prepared is dried to constant weight, bottom the weighing botle of constant weight, puts into the granule of thick about 2mm, accurately
The exsiccator weighing the supersaturated solution being placed on the sulphuric acid filling 6 kinds of variable concentrations respectively listed by table or different salt (claims
Measuring bottle lid is opened), in 25 DEG C of constant incubators, moisture absorption is to constant weight, precision weighing, calculates its Moisture percentage.The results are shown in Table
22。
With relative humidity as abscissa, hydroscopicity is vertical coordinate, draws sucting wet curve, sees Figure 10.By sucting wet curve straight line
This curve tangent line is done at two ends, and two intersections of complex curve abscissas are critical relative humidity (CRH), and critical relative humidity is 60%, because of
This should control relative humidity at the environment pulverized, pelletize, pack and store and be less than 60%, and uses moistureproof good packaging.
Three, scale up test
Feed intake by 1000 preparation unit amount times raw materials, prepare by above-mentioned optimised process, manufacture experimently three batch pilot scale finished products, and
Detect by the requirement under quality standard and medicine granule item, the results are shown in Table 23,24.
The raw material input amount of 23 1000 preparation prescription amounts of table
Table 24 pilot scale finished product detection data
From scale up test result of study in table, use the moulding process optimized, its ratio of briquetting up to 90%, and three batches
The ratio of briquetting of finished product is basically identical, have detected the many index of finished product simultaneously, is computed in Radix Paeoniae Rubra Mongolian oak in peoniflorin and Herba Polygoni cymosi
The rate of transform of Pi Su respectively reaches 71% and 52%, shows that this technique is simple, feasible, stable.
Four, this preparation prescription is used for clinical experimental study, and its research is as follows:
4.1, clinical data
4.1.1, physical data
126 example patients, year mean age (33.5 ± 6.3).
4.1.2, diagnostic criteria
With reference to the 3rd academic conference revised standard of department of obstetrics and gynecology Professional Committee of CAIM (Chinese Association Of Integrative Medicine).All cases
All combine clinical gynecologial examination, B-type ultrasonography diagnosis, some cases combine CT, MRI, CA125 value, laparoscopy and
Postoperative pathological examination inspection is diagnosed as endometriosis.
Waist and sacrum pain, dysmenorrhea 86 example in main clinic symptoms and sign 126 example patient, menoxenia 43 example, infertile 15
Example.Gynecologial examination has obvious painful tubercles 71 example, B ultrasonic prompting myometrial gland tumor 41 example, chocolate cyst of ovary 34 example, Qi Zhongshuan
Side person 16 example, cyst maximum gauge is 8.7cm.
4.2, treatment and observational technique
4.2.1, Therapeutic Method
(1) treatment
When observing clinical efficacy, use decoction.Compound recipe dragon pellet decoction use: Sanguis Draxonis 3g, Radix Et Rhizoma Rhei 12g, Fructus Corni 10g, when
Return 8g, Cortex Moutan 8g, Radix Aucklandiae 8g, Rhizoma Corydalis 8g, Radix Paeoniae Rubra 6g, Poria 10g, Rhizoma Curcumae 6g, Herba Polygoni cymosi 5g, Ramulus Cinnamomi 5g and Rhizoma Sparganii 5g,
Every day 1 dose.For ease of taking, by 10 agent medicines with decocting 3 times, gained concentration of liquid medicine becomes 1000mL, 4 DEG C of Refrigerator stores, every day 2
Secondary, each 50mL, heats when taking oral.
(2) course for the treatment of was 1 course for the treatment of with 6 months.
4.2.2, observation index and method
(1) main clinic symptoms and sign: the symptoms such as waist and sacrum pain, dysmenorrhea, menoxenia are pressed light and heavy degree marking,
Asymptomatic person 0 point;Mild 1 point;Medium disease 2 points;Serious symptom 3 points.Examine, obtained by ultrasound diagnosis according to gynecological's bimanual examination, three conjunctions
The sign such as painful tubercles, endometrial cyst and pelvic adhesion pathological changes is divided into gently, in, severe.Without obvious sign person 0 point;Slight 1
Point;Moderate 2 points;Severe 3 points.Gynecologial examination in every 4 weeks 1 time in drug administration process, ultrasound diagnosis 1 time in every 8 weeks, dynamically observe 2 groups of cases
Clinical symptoms and the degree of improvement of sign.
(2) observe drug side effect situation, follow up a case by regular visits to gestation and recurrence.
4.3, therapeutic outcome
4.3.1, criterion of therapeutical effect
The criterion of therapeutical effect formulated according to the 3rd academic conference of department of obstetrics and gynecology Professional Committee of CAIM (Chinese Association Of Integrative Medicine), 1.
Recovery from illness: symptom all disappears, the local such as pelvic lump sign disappears substantially, and Sterility patient is gestation or fertility in 3 years;2. show
Effect: symptom disappears substantially, and pelvic lump reduces, though or local sign exist, but infertile patient is become pregnant;The most effective: symptom
Alleviating, pelvic lump is without increasing or slightly reducing, and in drug withdrawal 3 months, symptom does not increases the weight of;The most invalid: cardinal symptom is unchanged or dislikes
Changing, local patholoic change has and increases the weight of trend.
4.3.2, result
The clinical data statistics of 126 example non-operative treatment gynecopathies, its total effective rate is 90.48%, 35 examples of wherein fully recovering
(29.36%), effective 48 examples (38.09%), effective 31 examples (24.60%).
The invention have benefit that: the Chinese medicine preparation of the treatment endometriosis of the present invention, there is invigorating blood circulation
The stasis of blood, the kidney invigorating takes off admittedly, and dissipate knot, effect of removing obstruction in the collateral to relieve pain.For married woman place block, silt resistance of suffering from a deficiency of the kidney, or caused by energy stagnation and blood stasis
Menoxenia, premenstrual inferior belly gas pain, acute through row pain, pain draws waist sacrum, tenderness, and pudendum sky falls, or blockage of menstruation, hypomenorrhea or pouring
Drenching endless, color is dark, has held clot under the arm, alleviation of pain under block, or with distending pain of the breast, headache and insomnia, hyposexuality, body of the tongue purple is dim, or
While there is ecchymosis, thin fur, all cards such as deep-thready pulse or string;Endometriosis, hysteromyoma is shown in above-mentioned all card persons.Its therapeutic effect shows
Writing, the clinical data statistics of 126 example non-operative treatment gynecopathies, its total effective rate is 90.48%, 35 examples of wherein fully recovering
(29.36%), effective 48 examples (38.09%), effective 31 examples (24.60%).In the treatment endometriosis of the present invention
Medicine preparation has the effect of good treatment endometriosis.The composition medicine of the present invention, is pharmacopeia and terrestrial reference is contained
Common medicine, its aboundresources.The Chinese medicine preparation of the treatment endometriosis of the present invention is preferably granule, facilitates patient
Take, real meaning accomplish " three little five just ", it is achieved the modernization of Chinese medicine.By to the extraction of this preparation, Study on Preparation,
Excellent have selected relatively reasonable extracting factor and preparation process condition.The preparation technology of the present invention is simple, feasible, stable,
Preparation condition gentleness is easy to control, simple to operate, it is easy to large-scale production.
Accompanying drawing explanation
Fig. 1 is the process chart of the present invention;
Fig. 2 is alcohol extract sample chromatogram figure in alcohol extraction selection process;
Fig. 3 is to lack Herba Polygoni cymosi negative sample chromatogram in alcohol extraction selection process;
Fig. 4 is Quercetin reference substance chromatogram in alcohol extraction selection process;
Fig. 5 is Quercetin canonical plotting in alcohol extraction selection process;
Fig. 6 is that water carries Aqueous extracts sample chromatogram figure in selection process;
Fig. 7 is that water carries scarce Radix Paeoniae Rubra negative sample chromatogram in selection process;
Fig. 8 is that water carries peoniflorin reference substance chromatogram in selection process;
Fig. 9 is that water carries peoniflorin canonical plotting in selection process;
Figure 10 is the intermediate sucting wet curve of the Chinese medicine granules for the treatment of endometriosis.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further introduced.
Embodiment 1
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 53g, Radix Et Rhizoma Rhei 99g,
Fructus Corni 198g, Radix Angelicae Sinensis 198g, Cortex Moutan 198g, Radix Aucklandiae 99g, Rhizoma Corydalis 99g, Radix Paeoniae Rubra 198g, Poria 293g, Rhizoma Curcumae 173g,
Herba Polygoni cymosi 105g, Ramulus Cinnamomi 99g and Rhizoma Sparganii 165g.Prepare according to following steps: weigh according to quantity Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and
Rhubarb medicinal material, adds 6~10 times amount 60%~80% ethanol, reflux, extract, 1~3 times, each 1~2h, filters, obtains alcohol extract, standby
With;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii according to quantity, add 6~10 times amount water, decoct
Boiling extraction 1~3 time, each 1~2h, filter, obtain Aqueous extracts, being evaporated to density through 75 DEG C is 1.05, obtains condensed water extract,
Adding ethanol, stir, controlling concentration of alcohol in feed liquid is 40%~60%, stands 12h, discards precipitation, obtain on precipitate with ethanol
Clear liquid, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentrated solution, concentrated solution 60 DEG C
~80 DEG C of vacuum drying 42~72h, obtain extractum extract, pulverized No. 5 sieves, and obtained powder, and added adjuvant and make various medicine
Thing preparation.
Embodiment 2
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 198g, Radix Et Rhizoma Rhei
495g, Fructus Corni 396g, Radix Angelicae Sinensis 396g, Cortex Moutan 396g, Radix Aucklandiae 330g, Rhizoma Corydalis 330g, Radix Paeoniae Rubra 396g, Poria 495g, cowherb
Art 297g, Herba Polygoni cymosi 990g, Ramulus Cinnamomi 330g and Rhizoma Sparganii 330g.Prepare according to following steps: weigh according to quantity Herba Polygoni cymosi, Fructus Corni,
Rhizoma Corydalis and rhubarb medicinal material, add 6 times amount 60% ethanol, reflux, extract, 1 time, each 2h, filter, obtain alcohol extract, standby;Claim according to quantity
Take Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii, first add 8 times amount water boiling and extraction 1 time, then
With 7 times amount water boiling and extraction 2 times, each 1.5h, filtering, obtain Aqueous extracts, being evaporated to density through 75 DEG C is 1.05, obtains concentration
Aqueous extracts, adds ethanol, stirs, and controlling concentration of alcohol in feed liquid is 40%, stands 12h, discards precipitation, obtain on precipitate with ethanol
Clear liquid, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentrated solution, concentrated solution 60 DEG C
Vacuum drying 57h, obtains extractum extract, pulverized No. 5 sieves, and obtained medicated powder, add solvable by the mass ratio of 1:1 in medicated powder
Property starch, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, makees wetting agent with the ethanol of 90% and pelletizes,
Grain is dried in 60 DEG C~80 DEG C, and secondary is pelletized, and crosses No. 1 and screens out bulky grain, crosses No. 5 and screen out fine powder, obtain granule.This preparation
Boiled water is taken after mixing it with water.Once two bags, three times on the one.Every packed 5g.
Embodiment 3
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 103g, Radix Et Rhizoma Rhei
412g, Fructus Corni 343g, Radix Angelicae Sinensis 275g, Cortex Moutan 275g, Radix Aucklandiae 175g, Rhizoma Corydalis 257g, Radix Paeoniae Rubra 223g, Poria 343g, cowherb
Art 223g, Herba Polygoni cymosi 155g, Ramulus Cinnamomi 223g and Rhizoma Sparganii 223g.Prepare according to following steps: weigh according to quantity Herba Polygoni cymosi, Fructus Corni,
Rhizoma Corydalis and rhubarb medicinal material, add 9 times amount, 8 times amount 80% ethanol, reflux, extract, 2 times, each 1h respectively, filter, obtain alcohol extract,
Standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii according to quantity, add respectively 7 times amount, 6
Times amount water, decocts and extracts 2 times, and each 1h filters, obtains Aqueous extracts, and being evaporated to density through 75 DEG C is 1.05, obtains condensed water and carries
Liquid, adds ethanol, stirs, and controlling concentration of alcohol in feed liquid is 60%, stands 12h, discards precipitation, obtain precipitate with ethanol supernatant
Liquid, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentrated solution, and concentrated solution 70 DEG C is true
Empty dry 60h, obtains extractum extract, pulverized No. 5 sieves, and obtained medicated powder, and added solubility by the mass ratio of 1:1 in medicated powder
Starch, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, and the ethanol of 90% is made wetting agent and pelletized, and granule exists
60 DEG C~80 DEG C gradually rise warming middle-JIAO and are dried, and secondary is pelletized, and crosses No. 1 and screens out bulky grain, crosses No. 5 and screen out fine powder, obtain granule.This
Preparation boiled water is taken after mixing it with water.Once two bags, three times on the one.Every packed 5g.
Embodiment 4
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 150g, Radix Et Rhizoma Rhei
350g, Fructus Corni 220g, Radix Angelicae Sinensis 230g, Cortex Moutan 300g, Radix Aucklandiae 250g, Rhizoma Corydalis 240g, Radix Paeoniae Rubra 260g, Poria 310g, cowherb
Art 200g, Herba Polygoni cymosi 800g, Ramulus Cinnamomi 260g and Rhizoma Sparganii 210g.Prepare according to following steps: weigh according to quantity Herba Polygoni cymosi, Fructus Corni,
Rhizoma Corydalis and rhubarb medicinal material, first add 10 times amount 70% alcohol reflux 1 time, then adds 9 times amount 70% alcohol reflux 2 times,
1.5h every time, filters, obtains alcohol extract, standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, osmanthus according to quantity
Branch and Rhizoma Sparganii, add 10 times amount water, decocts and extracts 1 time, and each 2h filters, obtains Aqueous extracts, and being evaporated to density through 75 DEG C is
1.05, obtain condensed water extract, add ethanol, stir, controlling concentration of alcohol in feed liquid is 50%, stands 12h, and it is heavy to discard
Form sediment, obtain precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentration
Liquid, concentrated solution 80 DEG C vacuum drying 42h, obtain extractum extract, pulverized No. 5 sieves, and obtained medicated powder, by the mass ratio of 1:1 to
Adding soluble starch in medicated powder, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, and the ethanol of 90% is made to moisten
Humectant is pelletized, and granule is dried in 60 DEG C~80 DEG C, and secondary is pelletized, and crosses No. 1 and screens out bulky grain, crosses No. 5 and screen out fine powder, obtain granule
Agent.This preparation boiled water is taken after mixing it with water.Once two bags, three times on the one.Every packed 5g.
Embodiment 5
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 80g, Radix Et Rhizoma Rhei 150g,
Fructus Corni 330g, Radix Angelicae Sinensis 305g, Cortex Moutan 350g, Radix Aucklandiae 180g, Rhizoma Corydalis 120g, Radix Paeoniae Rubra 360g, Poria 390g, Rhizoma Curcumae
210g, Herba Polygoni cymosi 500g, Ramulus Cinnamomi 120g and Rhizoma Sparganii 300g.Prepare according to following steps: weigh Herba Polygoni cymosi, Fructus Corni according to quantity, prolong
Rhizoma Corydalis and rhubarb medicinal material, add 8 times amount, 7 times amount 75% ethanol, reflux, extract, 2 times, each 1.5h respectively, filter, obtain alcohol extract,
Standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii according to quantity, add respectively 9 times amount, 8
Times amount water, decocts and extracts 2 times, and each 2h filters, obtains Aqueous extracts, and being evaporated to density through 75 DEG C is 1.05, obtains condensed water and carries
Liquid, adds ethanol, stirs, and controlling concentration of alcohol in feed liquid is 60%, stands 12h, discards precipitation, obtain precipitate with ethanol supernatant
Liquid, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains concentrated solution, and concentrated solution 60 DEG C is true
Empty dry 72h, obtains extractum extract, pulverized No. 5 sieves, and obtained medicated powder, and added solubility by the mass ratio of 1:1 in medicated powder
Starch, the aspartame accounting for medicated powder gross mass 0.2% with consumption makees correctives, and the ethanol of 90% is made wetting agent and pelletized, and granule exists
60 DEG C~80 DEG C gradually rise warming middle-JIAO and are dried, and secondary is pelletized, and crosses No. 1 and screens out bulky grain, crosses No. 5 and screen out fine powder, obtain granule.This
Preparation boiled water is taken after mixing it with water.Once two bags, three times on the one.Every packed 5g.
Embodiment 6
A kind of Chinese medicine preparation treating endometriosis, is made up of following crude drug: Sanguis Draxonis 135g, Radix Et Rhizoma Rhei
480g, Fructus Corni 270g, Radix Angelicae Sinensis 380g, Cortex Moutan 225g, Radix Aucklandiae 210g, Rhizoma Corydalis 300g, Radix Paeoniae Rubra 300g, Poria 370g, cowherb
Art 190g, Herba Polygoni cymosi 200g, Ramulus Cinnamomi 190g and Rhizoma Sparganii 180g.Prepare according to following steps: weigh according to quantity Herba Polygoni cymosi, Fructus Corni,
Rhizoma Corydalis and rhubarb medicinal material, first add 9 times amount 65% alcohol reflux 1 time, then adds 8 times amount 65% alcohol reflux 2 times, often
Secondary 2h, filters, obtains alcohol extract, standby;Weigh according to quantity Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and
Rhizoma Sparganii, first adds 7 times amount soak by water 1 time, then adds 6 times amount water boiling and extraction 2 times, each 1h, filters, obtains Aqueous extracts, subtract through 75 DEG C
It is 1.05 that pressure is concentrated into density, obtains condensed water extract, adds ethanol, stirs, and controlling concentration of alcohol in feed liquid is 40%
~60%, stand 12h, discard precipitation, obtain precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, 75 DEG C of concentrating under reduced pressure
It is 1.25 to density, obtains concentrated solution, concentrated solution 70 DEG C vacuum drying 72h, obtain extractum extract, pulverized No. 5 sieves, and obtained medicine
Powder, adds soluble starch by the mass ratio of 1:1 in medicated powder, and the aspartame accounting for medicated powder gross mass 0.2% with consumption is made
Correctives, the ethanol of 90% make wetting agent pelletize, granule 60 DEG C~80 DEG C gradually rise warming middle-JIAO be dried, secondary pelletize, cross No. 1 sieve
Except bulky grain, cross No. 5 and screen out fine powder, obtain granule.This preparation boiled water is taken after mixing it with water.Once two bags, three times on the one.Every packed 5g.
Claims (8)
1. the Chinese medicine preparation treating endometriosis, it is characterised in that: count by weight, by following crude drug system
Become: Sanguis Draxonis 53~198 parts, Radix Et Rhizoma Rhei 99~495 parts, Fructus Corni 198~396 parts, Radix Angelicae Sinensis 198~396 parts, Cortex Moutan 198~
396 parts, the Radix Aucklandiae 99~330 parts, Rhizoma Corydalis 99~330 parts, Radix Paeoniae Rubra 198~396 parts, Poria 293~495 parts, Rhizoma Curcumae 173~
297 parts, Herba Polygoni cymosi 105~990 parts, Ramulus Cinnamomi 99~330 parts and Rhizoma Sparganii 165~330 parts.
A kind of Chinese medicine preparation treating endometriosis the most according to claim 1, it is characterised in that: by weight
Number meter, is made up of following crude drug: Sanguis Draxonis 103 parts, Radix Et Rhizoma Rhei 412 parts, Fructus Corni 343 parts, Radix Angelicae Sinensis 275 parts, Cortex Moutan 275
Part, the Radix Aucklandiae 175 parts, Rhizoma Corydalis 257 parts, Radix Paeoniae Rubra 223 parts, 343 parts of Poria, Rhizoma Curcumae 223 parts, Herba Polygoni cymosi 155 parts, Ramulus Cinnamomi 223 parts
With Rhizoma Sparganii 223 parts.
A kind of Chinese medicine preparation treating endometriosis the most according to claim 1 and 2, it is characterised in that: described
Preparation be make excipient with soluble starch, 0.2% aspartame makees correctives, 90% ethanol is made as wetting agent granule
Agent.
4. the preparation method of the Chinese medicine preparation for the treatment of endometriosis as claimed in claim 1 or 2, it is characterised in that:
Weigh Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and rhubarb medicinal material according to quantity, add ethanol, reflux, extract, filter, obtain alcohol extract, standby;Press
Amount weighs Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and Rhizoma Sparganii, adds water, and decocts and extracts, and filters,
Aqueous extracts, through concentrating under reduced pressure, obtains condensed water extract, adds ethanol, stir, and stands, discards precipitation, obtain precipitate with ethanol supernatant
Liquid, standby;Alcohol extract mixes with precipitate with ethanol supernatant, concentrating under reduced pressure, obtains concentrated solution, and concentrated solution is vacuum dried, and obtains extractum extract,
Pulverize and sieve, obtain medicated powder, add adjuvant and make various pharmaceutical preparation.
The preparation method of the Chinese medicine preparation for the treatment of endometriosis the most according to claim 4, it is characterised in that: press
Amount weighs Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and rhubarb medicinal material, adds 6~10 times amount 60%~80% ethanol, reflux, extract, 1~3
Secondary, each 1~2h, filter, obtain alcohol extract, standby;Weigh Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, cowherb according to quantity
Art, Ramulus Cinnamomi and Rhizoma Sparganii, add 6~10 times amount water, decocts and extracts 1~3 time, and each 1~2h filter, obtain Aqueous extracts, through 75 DEG C of decompressions
Being concentrated into density is 1.05, obtains condensed water extract, adds ethanol, stirs, control concentration of alcohol in feed liquid be 40%~
60%, stand 12h, discard precipitation, obtain precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to
Density is 1.25, obtains concentrated solution, concentrated solution 60 DEG C~80 DEG C vacuum drying 72~42h, obtains extractum extract, pulverized No. 5 sieves,
Obtain medicated powder, add adjuvant and make various pharmaceutical preparation.
The preparation method of the Chinese medicine preparation for the treatment of endometriosis the most according to claim 5, it is characterised in that: press
Amount weighs Herba Polygoni cymosi, Fructus Corni, Rhizoma Corydalis and rhubarb medicinal material, adds 9 times amount, 8 times amount 80% ethanol respectively, reflux, extract, 2 times, often
Secondary 1h, filters, obtains alcohol extract, standby;Weigh according to quantity Sanguis Draxonis, Radix Angelicae Sinensis, Cortex Moutan, the Radix Aucklandiae, Radix Paeoniae Rubra, Poria, Rhizoma Curcumae, Ramulus Cinnamomi and
Rhizoma Sparganii, adds 7 times amount, 6 times amount water respectively, decocts and extracts 2 times, and each 1h filters, obtains Aqueous extracts, be evaporated to close through 75 DEG C
Degree is 1.05, obtains condensed water extract, adds ethanol, stirs, and controlling concentration of alcohol in feed liquid is 60%, stands 12h, abandons
Go precipitation, obtain precipitate with ethanol supernatant, standby;Alcohol extract mixes with precipitate with ethanol supernatant, and 75 DEG C are evaporated to density is 1.25, obtains dense
Contracting liquid, concentrated solution 70 DEG C vacuum drying 60h, obtain extractum extract, pulverized No. 5 sieves, and obtained medicated powder, add adjuvant and make respectively
Plant pharmaceutical preparation.
7., according to the preparation method of the Chinese medicine preparation treating endometriosis described in claim 4 or 5, its feature exists
In: adding soluble starch in medicated powder by the mass ratio of 1:1, the aspartame accounting for medicated powder gross mass 0.2% with consumption is made
Correctives, 90% ethanol makees wetting agent and pelletizes, and granule is dried in 60 DEG C~80 DEG C, and secondary is pelletized, and crosses and screens out bulky grain and except carefully
Powder, obtains granule.
The preparation method of the Chinese medicine preparation for the treatment of endometriosis the most according to claim 7, it is characterised in that: press
The mass ratio of 1:1 adds soluble starch in medicated powder, and the aspartame accounting for medicated powder gross mass 0.2% with consumption makees taste masking
Agent, 90% ethanol make wetting agent pelletize, granule 60 DEG C~80 DEG C gradually rise warming middle-JIAO be dried, secondary pelletize, cross No. 1 screen out big
Grain, crosses No. 5 and screens out fine powder, obtain granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610632470.9A CN106110206B (en) | 2016-08-04 | 2016-08-04 | Traditional Chinese medicine preparation for treating endometriosis and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610632470.9A CN106110206B (en) | 2016-08-04 | 2016-08-04 | Traditional Chinese medicine preparation for treating endometriosis and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106110206A true CN106110206A (en) | 2016-11-16 |
CN106110206B CN106110206B (en) | 2021-03-09 |
Family
ID=57254638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610632470.9A Expired - Fee Related CN106110206B (en) | 2016-08-04 | 2016-08-04 | Traditional Chinese medicine preparation for treating endometriosis and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106110206B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432530A (en) * | 2013-09-06 | 2013-12-11 | 梁怡芃 | Traditional Chinese medicine composition for treating endometriosis and preparation method thereof |
-
2016
- 2016-08-04 CN CN201610632470.9A patent/CN106110206B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432530A (en) * | 2013-09-06 | 2013-12-11 | 梁怡芃 | Traditional Chinese medicine composition for treating endometriosis and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
王秀萍: "自拟活血散结汤治疗子宫内膜异位症120例", 《中国医药指南》 * |
盖德美: "桂枝茯苓丸化裁妇科临证心悟", 《山东中医杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN106110206B (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169881B (en) | Chinese medicament health product for supplementing female hormone for women during menopause and preparation method thereof | |
CN103393821B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
CN104258066A (en) | Traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding, and preparation method thereof | |
CN101269170B (en) | Medicament for treating climacteric syndrome and preparation method thereof | |
CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
CN105250619A (en) | Traditional Chinese medicine for treating intrinsic endometriosis and preparation method thereof | |
CN1315504C (en) | Extract for treating functional indigestion and its medicine composition | |
CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
CN100490867C (en) | Traditional Chinese medicine composition for treating gynecologic inflammation and its preparing method | |
CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
CN106110206A (en) | A kind of Chinese medicine preparation treating endometriosis and preparation method thereof | |
CN101647901B (en) | Oral Chinese herba preparation for treating postpartum qi and blood deficiency of woman and production method thereof | |
CN104984184A (en) | Medicine composite for treating child appendicular abscess and preparation method thereof | |
CN105998290A (en) | Traditional Chinese medicine composition for treating early woman amenorrhea and preparing method thereof | |
CN106038802A (en) | Preparation method of traditional Chinese medicinal composition for treating premature ovarian failure of women and traditional Chinese medicinal composition | |
CN106420891A (en) | Application of folium cortex eucommiae general flavone in preparation of medicine for treating perimenopausal syndrome | |
CN106177451A (en) | The Chinese medicine suppository preparation method for the treatment of women's ovary senilism and suppository thereof | |
CN105194563B (en) | A kind of combination medicament and preparation method thereof for prostatic disorders | |
CN104398987A (en) | Chinese medicinal composition for treating cold accumulation-caused blood stasis type dysmenorrhea | |
CN104815310A (en) | Medicine for removing embryonic tissue residues | |
CN105232997A (en) | Chinese herba preparation used for treating endometritis and preparing method | |
CN105535674A (en) | A medicine for treating chronic cervicitis | |
CN117257867A (en) | Traditional Chinese medicine composition for treating infertility caused by oviduct obstruction, and preparation method and application thereof | |
CN104922601A (en) | Traditional Chinese medicine preparation for treating liver stagnation blood heat type uterine bleeding and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210309 Termination date: 20210804 |